The online version of this article (doi:10.1186/s12893-015-0096-z) contains supplementary material, which is available to authorized users.
Dr Verma has received research grant support and/or speaker/consulting honoraria from AstraZeneca, Bayer, Boehringer Ingelheim, GlaxoSmithKline, Merck, Pfizer and Sanofi. Dr Goodman has received research grant support and/or speaker/consulting honoraria from AstraZeneca, Bristol-Myers Squibb/Sanofi, and Eli Lilly/Daiichi-Sankyo. Dr Mehta has received research grant support and/or speaker/consulting honoraria from AstraZeneca, Boston Scientific, Eli Lilly, and Merck. Dr Ruel has received research grant support from Bristol-Myers Squibb/Sanofi. Dr M Gupta has received research grant support and/or speaker/consulting honoraria from AstraZeneca, Eli Lilly, Merck, and Bristol-Myers Squibb/Sanofi. None of the disclosures pertain to the current investigation which received no specific funding. All other authors have nothing to disclose with regard to commercial support.
SV and JOF conceived and designed the study. NG, HT and JOF acquired the data. SV, SGG, SRM, DAL, MR, MG, BY, MAO and JOF analyzed and interpreted the data. SV, NG, HT and JOF drafted the original manuscript. SV, SGG, SRM, DAL, MR, MG, BY, MAO, HT and JOF critically revised the manuscript. All authors have read and approved the final version of the manuscript. All authors agree to be accountable for all aspects of the work ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.
We assessed the effectiveness of dual antiplatelet therapy (DAPT) post elective or urgent (i.e., post acute coronary syndrome [ACS]) coronary artery bypass graft surgery (CABG).
We systematically searched MEDLINE, EMBASE, and the Cochrane Registry from inception to August 2015. Randomized controlled trials (RCTs) in adults undergoing CABG comparing either dual vs. single antiplatelet therapy or higher- vs. lower-intensity DAPT were identified.
Nine RCTs (n = 4,887) with up to 1y follow-up were included. Five RCTs enrolled patients post-elective CABG (n = 986). Two multi-centre RCTs enrolled ACS patients who subsequently underwent CABG (n = 2,155). These 7 RCTs compared clopidogrel plus aspirin to aspirin alone. Two other multi-centre RCTs reported on ACS patients who subsequently underwent CABG comparing higher intensity DAPT with either ticagrelor (n = 1,261) or prasugrel (n = 485) plus aspirin to clopidogrel plus aspirin. Post-operative anti-platelet therapy was started when chest tube bleeding was no longer significant, typically within 24–48 h. There were no differences in all-cause mortality in clopidogrel plus aspirin vs. aspirin RCTs; conversely, all-cause mortality was significantly lower in ticagrelor and prasugrel vs. clopidogrel RCTs (risk ratio[RR] 0.49, 95 % confidence interval[CI] 0.33–0.71, p = 0.0002; 2 RCTs, n = 1695; I 2 = 0 %; interaction p < 0.01 compared to clopidogrel plus aspirin vs aspirin RCTs). There were no differences in myocardial infarctions, strokes, or composite outcomes. Overall, major bleeding was not significantly increased (RR 1.31, 95 % CI 0.81–2.10, p = 0.27; 7 RCTs, n = 4500). There was heterogeneity (I 2 = 42 %) due almost entirely to higher bleeding reported for the prasugrel RCT which included mainly CABG-related major bleeding (RR 3.15, 95 % CI 1.45–6.87, p = 0.004; 1 RCT, n = 437).
Most RCT data for DAPT post CABG is derived from subgroups of ACS patients in DAPT RCTs requiring CABG who resume DAPT post-operatively. Limited RCT data with heterogeneous trial designs suggest that higher intensity (prasugrel or ticagrelor) but not lower intensity (clopidogrel) DAPT is associated with an approximate 50 % lower mortality in ACS patients who underwent CABG based on post-randomization subsets from single RCTs. Large prospective RCTs evaluating the use of DAPT post-CABG are warranted to provide more definitive guidance for clinicians.
Additional file 1: Description of Excluded RCTs. (DOC 63 kb)12893_2015_96_MOESM1_ESM.doc
Jneid H, Anderson JL, Wright RS, Adams CD, Bridges CR, Casey Jr DE, et al. ACCF/AHA focused update of the guideline for the management of patients with unstable angina/non-ST-elevation myocardial infarction (updating the 2007 guideline and replacing the 2011 focused update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2012;60:645–81.
Groeneveld PW, Hlatky MA. Commentary. Evid Based Med. 2001;6:114. CrossRef
Sterne JAC, Egger M, Moher D. Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0. Chapter 10: Addressing reporting biases. In . Edited by Higgins JPT, Green S: The Cochrane Collaboration; 2011.
Sun JC, Teoh KH, Lamy A, Sheth T, Ellins ML, Jung H, et al. Randomized trial of aspirin and clopidogrel versus aspirin alone for the prevention of coronary artery bypass graft occlusion: the Preoperative Aspirin and Postoperative Antiplatelets in Coronary Artery Bypass Grafting study. Am Heart J. 2010;160:1178–84. CrossRefPubMed
Held C, Asenblad N, Bassand JP, Becker RC, Cannon CP, Claeys MJ, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes undergoing coronary artery bypass surgery: results from the PLATO (Platelet Inhibition and Patient Outcomes) trial. J Am Coll Cardiol. 2011;57:672–84. CrossRefPubMed
Saw J, Topol EJ, Steinhubl SR, Brennan D, Berger PB, Moliterno DJ, et al. Comparison of long-term usefulness of clopidogrel therapy after the first percutaneous coronary intervention or coronary artery bypass grafting versus that after the second or repeat intervention. Am J Cardiol. 2004;94:623–5. CrossRefPubMed
Fox KA, Mehta SR, Peters R, Zhao F, Lakkis N, Gersh BJ, et al. Benefits and risks of the combination of clopidogrel and aspirin in patients undergoing surgical revascularization for non-ST-elevation acute coronary syndrome: the Clopidogrel in Unstable angina to prevent Recurrent ischemic Events (CURE) Trial. Circulation. 2004;110:1202–8. CrossRefPubMed
Mannacio VA, Di Tommaso L, Antignan A, De Amicis V, Vosa C. Aspirin plus clopidogrel for optimal platelet inhibition following off-pump coronary artery bypass surgery: results from the CRYSSA (prevention of Coronary arteRY bypaSS occlusion After off-pump procedures) randomised study. Heart. 2012;98:1710–5. CrossRefPubMed
Mujanovic E, Nurkic M, Caluk J, Terzic I, Kabil E, Bergsland J. The effect of combined clopidogrel and aspirin therapy after off-pump coronary surgery: a pilot study. Innovations (Phila). 2009;4:265–8. CrossRef
Wang X-Z, Gong X-X, Zhu T-T, Li C-J, Yang Z-J. Effect of aspirin plus clopidogrel therapy on aspirin resistance after off-pump coronary artery bypass surgery [Chinese]. Acta Acad Med Sinicae. 2013;35:495–502.
Saw JW, Wong G, Mayo J, Bernstein V, Mancini GB, Ye J, et al. Ticagrelor and Aspirin for the Prevention of Cardiovascular Events After Coronary Artery Bypass Surgery: The TAP-CABG Study. J Am Coll Cardiol. 2015;65:A1638. CrossRef
Thopte OS, Patil SP, Deshmukh RS. A study of aspirin plus clopidogrel versus aspirin alone on saphenous vein graft patency after coronary artery bypass graft surgery-an angiographic follow-up after three months. Indian Heart Journal. 2014;66:S22. CrossRef
Wang X, Gong X, Zhu T, Zhang Q, Zhang Y, Wang X, et al. Clopidogrel improves aspirin response after off-pump coronary artery bypass surgery. J Biomed Res. 2014;28:108–13. PubMed
David JL, Limet R. Antiplatelet activity of clopidogrel in coronary artery bypass graft surgery patients. Thromb Haemost. 1999;82:1417–21. PubMed
Suwalski G, Smoczycski R, Banach M, Gryszko L, Szaaacski P, Krawczyk K, Hendzel P. Aspirin versus clopidogrel after off-pump coronary artery bypass grafting: Prospective, randomized head-to-head trial. In: 15th Annual Meeting of the International Society for Minimally Invasive Cardiothoracic Surgery . vol. 7. Los Angeles; 2012: 138.
Tetik S, Ak K, Isbir S, Eksioglu-Demiralp E, Arsan S, Iqbal O, et al. Clopidogrel provides significantly greater inhibition of platelet activity than aspirin when combined with atorvastatin after coronary artery bypass grafting: a prospective randomized study. Clin Appl Thromb Hemost. 2010;16:189–98. CrossRefPubMed
Cornelissen J, Kirtland S, Lim E, Goddard M, Bellm S, Sheridan K, et al. Biological efficacy of low against medium dose aspirin regimen after coronary surgery: analysis of platelet function. Thromb Haemost. 2006;95:476–82. PubMed
Cannon CP, Husted S, Harrington RA, Scirica BM, Emanuelsson H, Peters G, et al. Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: primary results of the DISPERSE-2 trial. J Am Coll Cardiol. 2007;50:1844–51. CrossRefPubMed
Wiviott SD, Antman EM, Winters KJ, Weerakkody G, Murphy SA, Behounek BD, et al. Randomized comparison of prasugrel (CS-747, LY640315), a novel thienopyridine P2Y12 antagonist, with clopidogrel in percutaneous coronary intervention: results of the Joint Utilization of Medications to Block Platelets Optimally (JUMBO)-TIMI 26 trial. Circulation. 2005;111:3366–73. CrossRefPubMed
Whellan DJ, Tricoci P, Chen E, Huang Z, Leibowitz D, Vranckx P, et al. Vorapaxar in acute coronary syndrome patients undergoing coronary artery bypass graft surgery: subgroup analysis from the TRACER trial (Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome). J Am Coll Cardiol. 2014;63:1048–57. CrossRefPubMed
Rafiq S, Johansson PI, Zacho M, Stissing T, Kofoed K, Lilleor NB, et al. Thrombelastographic haemostatic status and antiplatelet therapy after coronary artery bypass surgery (TEG-CABG trial): assessing and monitoring the antithrombotic effect of clopidogrel and aspirin versus aspirin alone in hypercoagulable patients: study protocol for a randomized controlled trial. Trials. 2012;13:48. CrossRefPubMedPubMedCentral
Eli Lilly and Company, Sankyo D. Effient (Prasugrel) Acute Coronary Syndromes Managed by Percutaneous Coronary Intervention. 2009. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/CardiovascularandRenalDrugsAdvisoryCommittee/ucm129219.pdf.
Goodnough LT, Smith PK, Levy JH, Poston RS, Short MA, Weerakkody GJ, et al. Transfusion outcomes in patients undergoing coronary artery bypass grafting treated with prasugrel or clopidogrel: TRITON-TIMI 38 retrospective data analysis. J Thorac Cardiovasc Surg. 2013;145:1077–82. e1074. CrossRefPubMed
Gurbel PA, Bliden KP, Butler K, Tantry US, Gesheff T, Wei C, et al. Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study. Circulation. 2009;120:2577–85. CrossRefPubMed
Husted S, James S, Becker RC, Horrow J, Katus H, Storey RF, et al. Ticagrelor versus clopidogrel in elderly patients with acute coronary syndromes: a substudy from the prospective randomized PLATelet inhibition and patient Outcomes (PLATO) trial. Circ Cardiovasc Qual Outcomes. 2012;5:680–8. CrossRefPubMed
Li JH, Aikeremu MT, Zhang MM, Yilihamu A. Effectiveness and Safety of Dual Anti-platelet Therapy after Coronary Artery Bypass Grafting: A Meta-Analysis [Chinese]. Chin J Evid-based Med. 2014;14:958–65.
Ma J, Xu W-J, Xu G-P. Impact of perioperative use of clopidogrel on coronary bypass grafting patients: a meta-analysis. Chin J Evid-Based Med. 2013;13:827–35.
Gurbuz AT, Zia AA, Vuran AC, Cui H, Aytac A. Postoperative clopidogrel improves mid-term outcome after off-pump coronary artery bypass graft surgery: a prospective study. Eur J Cardio-thorac Surg. 2006;29:190–5. CrossRef
- Should dual antiplatelet therapy be used in patients following coronary artery bypass surgery? A meta-analysis of randomized controlled trials
Shaun G. Goodman
Shamir R. Mehta
David A. Latter
Jan O. Friedrich
- BioMed Central
Neu im Fachgebiet Chirurgie
Mail Icon II